130 likes | 135 Views
Explore the efficacy of Daclatasvir and Sofosbuvir for HCV GT 1-4 and HIV coinfection. Results and dosing details from the ALLY-2 trial. Comprehensive analysis for treatment-naïve and experienced patients.
E N D
Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Sofosbuvir in HCV GT 1-4 and HIV CoinfectionALLY-2 Study Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Study Features Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Design 0 8 12 20 24 Week Treatment-Naïve N = 101 Daclatasvir + Sofosbuvir SVR12 Treatment-Naïve N = 50 Daclatasvir + Sofosbuvir SVR12 Daclatasvir + Sofosbuvir Treatment-Experienced N = 52 SVR12 Drug DosingDaclatasvir: 60 mg once daily; with efavirenz and nevirapine the dose was increased to 90 mg once daily and with ritonavir-boosted protease inhibitors the dose was decreased to 30 mg once dailySofosbuvir: 400 mg once daily Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Patient Characteristics Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: HIV Characteristics Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 1 SVR12, Genotype 1 31/41 43/44 80/83 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial:Results SVR12, Genotype 1 and subtypes 31/41 43/44 28/35 32/33 3/6 11/11 80/83 68/71 12/12 n=11 had missing or inconclusive findings for cirrhosis & not included in denominators Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 1 SVR12, Genotype 1, by Liver Status 70/72 8/9 28/36 2/4 28/28 12/13 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 2 SVR12, Genotype 2 5/6 2/2 11/11 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 3 SVR12, Genotype 3 2/3 4/4 6/6 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Results for Genotype 4 SVR12, Genotype 4 No GT4 patients enrolled in this arm 2/2 1/1 Abbreviations: DCV = daclatasvir; SOF = sofosbuvir Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
Daclatasvir + Sofosbuvir for HCV GT 1-4 and HIV CoinfectionALLY-2 Trial: Conclusion Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.
This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.